SCHEMBL8903178

SCHEMBL8903178

COC(=O)C1=CC=CC=NO1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
CA1 P00915 4/20 0.31
CA2 P00918 4/20 0.31
CA12 O43570 3/20 0.31
CA7 P43166 3/20 0.31
CA9 Q16790 3/20 0.31
CA14 Q9ULX7 3/20 0.31
TDP1 Q9NUW8 2/20 0.31
KDM6B O15054 1/20 0.31
KDM5C P41229 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31
KDM3A Q9Y4C1 1/20 0.31
MAPK1 P28482 2/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27873677 0.71 ALDH1A1 (0.34) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL29065453 0.68 NPSR1 (0.38) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL28348598 0.68 NPSR1 (0.34) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL27750716 0.67 TSHR (0.33) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL29065452 0.66 NPSR1 (0.44) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL27731317 0.65 TSHR (0.32) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL17822846 0.65 KDM4E (0.34) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL5902597 0.65
SCHEMBL30112181 0.64 NPSR1 (0.34) NPSR1KDM4EALDH1A1TSHRCA1
SCHEMBL4337074 0.64 NPSR1 (0.34) NPSR1KDM4EALDH1A1TSHRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105884758-B Tricyclic compounds and their use in medicine 广东东阳光药业有限公司 2019-12-10 CN disclosed
US-5672599-A DUAL ACTION ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS BRISTOL-MYERS SQUIBB CO. (US) 1997-09-30 US disclosed